Stifel Nicolaus Issues Positive Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price

Key Points

• Stifel Nicolaus raised AbCellera’s price target from $8 to $9 and maintained a “buy” rating, implying 44.76% upside from the stock’s $6.22 price. The analyst consensus is “Moderate Buy,” with an average target of $9.40.
• Analyst sentiment is mixed but generally positive, with Cantor Fitzgerald raising its target to $12 and Benchmark and JonesTrading issuing “buy” ratings, while some firms maintain “sell” views.
• AbCellera missed second-quarter expectations, reporting a $0.18 per-share loss versus the projected $0.14 loss and revenue of $4.05 million versus the $7.85 million estimate. Investors are also watching for Phase II data on ABCL635 and more than $110 million in upfront payments from new collaborations.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) had its price target lifted by research analysts at Stifel Nicolaus from $8.00 to $9.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price objective points to a potential upside of 44.76% from the company's current price.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald increased their target price on AbCellera Biologics from $11.00 to $12.00 and gave the stock an "overweight" rating in a research note on Thursday. Wall Street Zen downgraded AbCellera Biologics from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Benchmark upgraded AbCellera Biologics from a "hold" rating to a "buy" rating and set a $11.00 price target for the company in a research note on Tuesday, July 7th. JonesTrading started coverage on AbCellera Biologics in a research report on Friday, April 10th. They set a "buy" rating and a $11.00 price objective on the stock. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of AbCellera Biologics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $9.40.

AbCellera Biologics Price Performance

NASDAQ:ABCL traded up $0.30 during mid-day trading on Thursday, reaching $6.22. 2,080,425 shares of the company's stock traded hands, compared to its average volume of 5,670,690. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -12.95 and a beta of 1.20. The company has a 50 day moving average price of $6.19 and a 200-day moving average price of $4.66. AbCellera Biologics has a 12-month low of $2.74 and a 12-month high of $8.44.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.04). AbCellera Biologics had a negative return on equity of 14.86% and a negative net margin of 181.75%.The company had revenue of $4.05 million during the quarter, compared to the consensus estimate of $7.85 million. As a group, analysts forecast that AbCellera Biologics will post -0.67 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Handelsbanken Fonder AB grew its position in shares of AbCellera Biologics by 27.8% during the 2nd quarter. Handelsbanken Fonder AB now owns 147,900 shares of the company's stock valued at $1,161,000 after acquiring an additional 32,200 shares during the period. Bank of America Corp DE raised its stake in shares of AbCellera Biologics by 13.9% in the first quarter. Bank of America Corp DE now owns 2,999,936 shares of the company's stock worth $10,470,000 after buying an additional 367,064 shares during the period. Royal Bank of Canada lifted its position in shares of AbCellera Biologics by 5.6% during the 1st quarter. Royal Bank of Canada now owns 394,753 shares of the company's stock valued at $1,378,000 after buying an additional 20,897 shares in the last quarter. SEB Asset Management AB bought a new position in shares of AbCellera Biologics during the 1st quarter valued at approximately $1,188,000. Finally, Hsbc Holdings PLC increased its holdings in AbCellera Biologics by 22.6% in the 1st quarter. Hsbc Holdings PLC now owns 143,472 shares of the company's stock worth $499,000 after acquiring an additional 26,441 shares in the last quarter. 61.42% of the stock is currently owned by institutional investors.

Key Stories Impacting AbCellera Biologics

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on AbCellera from $11 to $12 and maintained an “overweight” rating. The new target implies substantial potential upside from the stock’s $5.92 reference price, signaling confidence in the company’s longer-term outlook. Benzinga analyst price-target update
• Positive Sentiment: AbCellera expects to report topline Phase II data for ABCL635 soon. The company also announced new T-cell engager collaborations that are expected to provide more than $110 million in upfront cash, improving near-term financial flexibility and potentially validating its antibody-discovery platform. AbCellera collaboration and ABCL635 update
• Neutral Sentiment: Investors are awaiting additional details from AbCellera’s Q2 earnings call regarding its collaboration pipeline, cash position and upcoming clinical milestones. Q2 2026 earnings call transcript
• Negative Sentiment: Q2 financial results missed expectations. AbCellera reported a loss of $0.18 per share versus the consensus estimate of a $0.14 loss, while revenue of $4.05 million fell well short of the $7.85 million forecast. The larger loss and sharply lower revenue highlight continued operating pressure and may limit gains until clinical and partnership catalysts deliver results. AbCellera Q2 2026 business results

About AbCellera Biologics

AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source